Tarceva blev i begge undersøgelser sammenlignet med placebo (virkningsløs behandling), og den vigtigste målestok for virkningen var ‘ medianoverlevelsestid ’ (tid, der gik, til 50% af patienterne stadig var i live).
In both studies, Tarceva was compared with placebo (a dummy treatment) and the main measure of effectiveness was ‘ median survival’ (time until 50% of the patients were still alive).